key: cord-0916079-j4pgpxoe
authors: Hassan, Ahmed O.; Kafai, Natasha M.; Dmitriev, Igor P.; Fox, Julie M.; Smith, Brittany K.; Harvey, Ian B.; Chen, Rita E.; Winkler, Emma S.; Wessel, Alex W.; Case, James Brett; Kashentseva, Elena; McCune, Broc T.; Bailey, Adam L.; Zhao, Haiyan; VanBlargan, Laura A.; Dai, Ya-Nan; Ma, Meisheng; Adams, Lucas J.; Shrihari, Swathi; Danis, Jonathan E.; Gralinski, Lisa E.; Hou, Yixuan J.; Schäfer, Alexandra; Kim, Arthur S.; Keeler, Shamus P.; Weiskopf, Daniela; Baric, Ralph S.; Holtzman, Michael J.; Fremont, Daved H.; Curiel, David T.; Diamond, Michael S.
title: A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2
date: 2020-08-19
journal: Cell
DOI: 10.1016/j.cell.2020.08.026
sha: 6777a5a1cbe7f111257c0ce7a1f62f91e7faf34e
doc_id: 916079
cord_uid: j4pgpxoe

Summary The Coronavirus Disease 2019 pandemic has made deployment of an effective vaccine a global health priority. We evaluated the protective activity of a chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike protein (ChAd-SARS-CoV-2-S) in challenge studies with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and mice expressing the human angiotensin-converting enzyme 2 receptor. Intramuscular dosing of ChAd-SARS-CoV-2-S induces robust systemic humoral and cell-mediated immune responses and protects against lung infection, inflammation, and pathology but does not confer sterilizing immunity, as evidenced by detection of viral RNA and induction of anti-nucleoprotein antibodies after SARS-CoV-2 challenge. In contrast, a single intranasal dose of ChAd-SARS-CoV-2-S induces high levels of neutralizing antibodies, promotes systemic and mucosal IgA and T cell responses, and virtually completely prevents SARS-CoV-2 infection in both the upper and lower respiratory tracts. Intranasal administration of ChAd-SARS-CoV-2-S is a candidate for preventing SARS-CoV-2 infection and transmission, and curtailing pandemic spread.

specific B cell responses, splenocytes were harvested and subjected to an ELISPOT analysis 147 with S protein. The ChAd-SARS-CoV-2-S vaccine induced S protein-specific IgG antibody-148 secreting cells in the spleen whereas the control vaccine did not (Fig 1I) .

To assess whether intramuscular vaccination could induce mucosal immune responses 150 in the lungs, mice were immunized with either ChAd-SARS-CoV-2-S or ChAd-control and 151 boosted similarly four weeks later. Lungs were harvested one-week post-boosting, and T cells 152 were analyzed by flow cytometry. Notably, we failed to detect an increase in IFNγ or granzyme 153 B producing CD8 + T cells in the lungs of ChAd-SARS-CoV-2-S vaccinated mice after re-154 stimulation ex vivo with a pool of S peptides (Fig 1J) or CD103 + CD69 + CD8 + cells that could 155 represent lung resident memory T cells (Fig 1K) . In the spleen, we also failed to detect 156 antibody-secreting plasma cells producing IgA against the S protein after immunization with (Fig 1M-N) 

Endogenous mouse ACE2 does not support viral entry (Letko et al., 2020) , and this system 167 enables productive SARS-CoV-2 infection in the mouse lung. Four-week-old BALB/c mice first 168 were immunized via an intramuscular route with ChAd-control or ChAd-SARS-CoV-2-S 169 vaccines. Approximately thirty days later, mice were administered 10 8 plaque-forming units 170 (PFU) of Hu-Ad5-hACE2 and anti-Ifnar1 monoclonal antibody (mAb) via intranasal and intraperitoneal routes, respectively. We also administered a single dose of anti-Ifnar1 mAb to -172 enhance lung pathogenesis in this model (Hassan et al., 2020) . We confirmed the absence of 173 cross-immunity between the ChAd and the Hu-Ad5 vector. Serum from ChAd-immunized mice 174 did not neutralize Hu-Ad5 infection (Fig S3A-B) .

Five days after Hu-Ad5-hACE2 transduction, mice were challenged via intranasal route 176 with 4 x 10 5 focus-forming units (FFU) of SARS-CoV-2 (Fig 2A) . At 4 days post-infection (dpi), dpi revealed a substantial decrease of SARS-CoV-2 RNA in pneumocytes of animals time point, viral RNA levels again were lower or absent in the lung and spleen of ChAd-SARSdata indicate that a single intramuscular immunization with ChAd-SARS-CoV-2-S results in 191 markedly reduced, but not abrogated, SARS-CoV-2 infection in the lungs of challenged mice.

We next assessed the effect of the vaccine on lung inflammation and disease. Several 

We then assessed for improved protection using a prime-boost vaccine regimen. BALB/c boosting (Fig 2G) .

immunity against SARS-CoV-2 in mice expressing hACE2 delivered by an adenoviral 214 vector. Mucosal immunization through the nasopharyngeal route can elicit local immune 215 responses including secretory IgA antibodies that confer protection at or near the site of 216 inoculation of respiratory pathogens (Neutra and Kozlowski, 2006) . To assess the 217 immunogenicity and protective efficacy of mucosal vaccination, five-week old BALB/c mice were 218 inoculated via intranasal route with 10 10 viral particles of ChAd-control or ChAd-SARS-CoV-2-S 219 (Fig 4A) . Serum samples were collected at four weeks post-immunization to evaluate humoral 220 immune responses. Intranasal immunization of ChAd-SARS-CoV-2-S but not ChAd-control 221 induced high levels of S-and RBD-specific IgG and IgA (Fig 4B-C) and SARS-CoV-2 222 neutralizing antibodies (GMT of 1/1,574) in serum (Fig 4D and S4A) . Antibodies from mice 223 immunized with ChAd-SARS-CoV-2-S equivalently neutralized a recombinant, luciferase-224 expressing variant of SARS-CoV-2 encoding a D614G mutation in the S protein ( Fig S4B) ; this 225 finding is important, because many circulating viruses contain this substitution, which is 226 associated with greater infectivity in cell culture (Korber et al., 2020) . We also assessed the 227 SARS-CoV-2-specific antibody responses in BAL fluid of immunized mice. BAL fluid from ChAd-228 SARS-CoV-2-S but not ChAd-control vaccinated mice showed high levels of S-and RBD-229 specific IgG and IgA antibodies (Fig 4E-F) including those with neutralizing activity (Fig 4G and   230   S4C ).

To assess T cell responses activated via mucosal immunization, mice were vaccinated 232 via intranasal route with either ChAd-SARS-CoV-2-S or ChAd-control and boosted similarly four 233 weeks later. Lungs were harvested one-week post-boosting, and T cells were analyzed by flow 234 cytometry. Re-stimulation ex vivo with a pool of S peptides resulted in a marked increase in antibody-secreting plasma cells producing IgA or IgG against the S protein after intranasal 240 immunization with ChAd-SARS-CoV-2-S (Fig 4J) . Of note, we observed an ~-5-fold higher 241 frequency of B cells secreting anti-S IgA than IgG.

We evaluated the protective efficacy of the ChAd vaccine after single-dose intranasal 243 immunization. At day 30 post-vaccination, mice were administered 10 8 PFU of Hu-Ad5-hACE2 244 and anti-Ifnar1 mAb as described above. Five days later, mice were challenged with 4 x 10 5 245 FFU of SARS-CoV-2. At 4 and 8 dpi, lungs, spleen, heart, nasal turbinates, and nasal washes 246 were harvested and assessed for viral burden. Intranasal delivery of the ChAd-SARS-CoV-2-S 247 vaccine demonstrated remarkable protective efficacy as judged by an absence of infectious 248 virus in the lungs (Fig 5A) and almost no measurable viral RNA in the lung, spleen, heart, nasal 249 turbinates, or nasal washes, as determined with subgenomic/genomic (N gene) or genomic only 250 (ORF1a gene) TaqMan probes (Fig 5B and S4D ). The very low viral RNA levels in the lung and 251 nasal turbinates at 4 dpi may reflect the input, non-replicating virus, as similar amounts were 

To begin to determine if sterilizing immunity might be achieved with intranasal delivery of vaccine vector, induction of humoral immune responses against NP after SARS-CoV-2 by an intranasal route or ChAd-control and ChAd-SARS-CoV-2-S mice vaccinated by an 267 intramuscular route (Fig 5E and S1C) . Remarkably, none of the mice immunized with ChAd-268 SARS-CoV-2-S via an intranasal route showed significant increases in anti-NP antibody 269 responses after SARS-CoV-2 infection (Fig 5E and S5) . with 10 3 FFU of SARS-CoV-2. At 4 dpi, lungs, spleen, heart, nasal turbinates, and nasal washes 290 were harvested and assessed for viral burden. Similar to that seen in BALB/c mice transiently 291 expressing hACE2, intranasal immunization of ChAd-SARS-CoV-2-S conferred remarkable 292 protection as judged by an absence of infectious virus in the lungs (Fig 6E) , no measurable viral 293 subgenomic/genomic RNA in the lungs or hearts, and very low levels of viral RNA in the nasal 294 turbinates or washes (Fig 6F) . Consistent with these results, after SARS-CoV-2 challenge, we 295 observed no induction of cytokine and chemokine mRNA (e.g., CCL2, CXCL1, CXCL10, 296 CXCL11, IL6, IFNβ, and IFNλ) in the lung homogenates of ChAd-SARS-CoV-2-S-immunized 297 compared to naïve mice, whereas ChAd-control vaccinated mice sustained high levels (Fig 6G) .

Collectively, these data suggest that a single intranasal immunization of ChAd-SARS-CoV-2-S 299 induces robust systemic and mucosal immunity that blocks SARS-CoV-2 infection in the upper 300 and lower respiratory tract of highly susceptible K18-hACE2 transgenic mice.

In this study, we evaluated intramuscular and intranasal administration of a replicationincompetent ChAd vector as a vaccine platforms for SARS-CoV-2. Single dose immunization of infectious virus in the lungs and substantially reduced viral RNA levels in lungs and other 

A single intranasal dose of ChAd-SARS-CoV-2-S conferred superior immunity against vaccine and dose (Fig 7) . Additionally, one intranasal dose of ChAd-SARS-CoV-2-S prevented 

We performed most challenge studies in mice transduced with hACE2 using a human Ad5 

Bars indicate median values, and dotted lines are the limit of detection (LOD) of the assays. I.

Spleens were harvested at 7 days post-boost, and SARS-CoV-2 spike-specific IgG+ antibody-467 secreting cells (ASC) frequency was measured by ELISPOT. CD8 + T cells in the lung were 468 assayed for IFNγ and granzyme B expression by flow cytometry after re-stimulation with an S 469 protein peptide pool (J). Lung CD8 + T cells also were assayed for expression of CD69 and 470 CD103 (K). L. Spleens were harvested at 7 days post-boosting, and SARS-CoV-2 spike-specific 

Whitney test: **, P < 0.01; ***, P < 0.001; **** P < 0.0001. See Figure S4 and Table S1. 

Mann-Whitney test: *, P < 0.05; **, P < 0.01; ***, P < 0.001; **** P < 0.0001; For E: ** P < 0.01, 541 **** P < 0.0001, ns; not significant; paired t test). See Figure S5 . 

CoV/USA_WA1/2020 strain) has been reported previously (Zost et al., 2020) , and the D614G 659 variant will be described elsewhere (R. Baric, manuscript in preparation). All work with infectious recommendations in the Guide for the Care and Use of Laboratory Animals of the National Virus inoculations were performed under anesthesia that was induced and maintained with 667 ketamine hydrochloride and xylazine, and all efforts were made to minimize animal suffering.

Female BALB/c (catalog 000651) and K18-hACE2 C57BL/6 (catalog 034860) mice were 669 purchased from The Jackson Laboratory. Four to five-week-old animals were immunized with 

(Goldbio) at 25°C, cells were lysed in 20 mM Tris-HCl pH 8.5, 1 M NaCl, 5 mM β-758 mercaptopethanol, and 5 mM imidazole for nickel-affinity purification. Following elution in the 759 prior buffer supplemented with 500 mM imidazole, the protein was purified to homogeneity using 760 size exclusion and, in some cases, cation exchange chromatography. SARS-CoV-2 RBD and S 761 ectodomain (S1/S2 furin cleavage site was disrupted, double proline mutations were introduced 762 into the S2 subunit, and foldon trimerization motif was incorporated) were cloned into pFM1.2 amino-9-ethylcarbazole (Sigma) substrate solution was added for spot development. The 

Dutta, A., Huang, C.T., Lin, C.Y., Chen, T.C., Lin, Y.C., Chang, C.S., and He, Y.C. (2016).

Sterilizing immunity to influenza virus infection requires local antigen-specific T cell response in in rhesus macaques inoculated with SARS-CoV-2. Nature.

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity

Immunogenicity and structures of a rationally 1061 designed prefusion MERS-CoV spike antigen

Alternative serotype adenovirus vaccine vectors 1065 elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors

China: a retrospective cohort study

A pneumonia outbreak associated with a new coronavirus of probable bat 1136 origin

Safety, tolerability, and immunogenicity of a recombinant adenovirus 1140 type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-1141 human trial

Highlights • Chimpanzee adenoviral vaccines encoding stabilized S induce neutralizing Abs • Chimpanzee adenoviral vaccines protect against SARS-CoV-2 infection and pneumonia • Intranasal vaccine delivery generates robust mucosal B and T cell responses • Intranasal ChAd-SARS-CoV-2 prevents upper and low respiratory tract infection eTOC Blurb Intranasal or intramuscular immunization of ChAd-SARS-CoV-2, a chimpanzee adenoviral vaccine encoding stabilized spike intramuscular prevents SARS-CoV-2 lung infection and pneumonia in mice